Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/nephrology.1.005
Commentary on: “Multiple Single Cannulation Technique of Arteriovenous Fistula: A Randomised Controlled Trial”
Ricardo Peralta1,*, Rui Sousa1, Bruno Pinto1, Pedro Gonçalves1, Carla Felix1, João Fazendeiro Matos1
- 1NephroCare Portugal, Fresenius Medical Care Portugal, Porto, Portugal
Corresponding Author
Ricardo Peralta, ricardo.peralta@fmc-ag.com
Received Date: August 03, 2021
Accepted Date: November 29, 2021
Peralta R, Sousa R, Pinto B, Gonçalves P, Felix C, Matos JF. Commentary on: “Multiple Single Cannulation Technique of Arteriovenous Fistula: A Randomised Controlled Trial”. Arch Nephrol Ren Stud. 2021;1(1):28-33.
Copyright: © 2021 Peralta R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Arteriovenous fistula, Buttonhole technique, Cannulation, Rope-ladder technique, Hemodialysis, MuST
Recommended Articles
How Well Do Hemodialysis Patients Respond to the BNT162b2 mRNA COVID-19 Vaccine?
In January 2020, the World Health Organization (WHO) classified COVID-19 to be a Public Health Emergency of International Concern and declared it a pandemic on March 11, 2020 [1]. Over one hundred and eighty-five million people have been infected by SARS-CoV-2 and roughly four million have died worldwide so far
Commentary on: “Multiple Single Cannulation Technique of Arteriovenous Fistula: A Randomised Controlled Trial”
One of the most important renal nursing procedures is the cannulation of a vascular access (VA), a procedure that is carried out on every single dialysis treatment. VA cannulation method is still a procedure that reflects local unit practices and the skill of the individual nurse. Despite the impact needling has on VA survival and patient outcome, no universal or standardized method has been proposed for cannulation.
Remdesivir in COVID-19 Patients with End Stage Renal Disease on Hemodialysis
To date, only glucocorticoids have been shown to reduce mortality in COVID-19. Use of remdesivir was associated with reduced length of stay in hospitalized COVID-19 patients. A deadly second wave in Asian countries has caused increased demand and usage of remdesivir in these countries. However, there is limited data about its efficacy in patients with severe renal dysfunction or end-stage renal disease on dialysis.
Blood Compatibility in Various Hemodialysis Membrane Materials: A Review
In hemodialysis therapy for end-stage kidney disease (ESKD) patients, blood and dialysate are brought into contact through the dialysis membrane to remove waste products and excess water. When blood contacts the dialysis membrane, blood cells, coagulation system, fibrinolysis system, kallikrein system, and complement system are activated. Therefore, dialysis membranes with excellent blood compatibility must be chosen to avoid such reactions to occur. In this article, we review blood compatibilities of each dialysis membrane material.